Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Invested Capital (2016 - 2025)

Historic Invested Capital for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $64.7 million.

  • Enanta Pharmaceuticals' Invested Capital fell 4975.93% to $64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.7 million, marking a year-over-year decrease of 4975.93%. This contributed to the annual value of $64.7 million for FY2025, which is 4975.93% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Invested Capital stood at $64.7 million for Q3 2025, which was down 4975.93% from $79.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Invested Capital's 5-year high stood at $436.0 million during Q1 2021, with a 5-year trough of $64.7 million in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' median Invested Capital value was $237.8 million (recorded in 2023), while the average stood at $245.6 million.
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 1027.98% in 2021, then tumbled by 4975.93% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Invested Capital stood at $384.4 million in 2021, then dropped by 21.74% to $300.8 million in 2022, then crashed by 36.22% to $191.9 million in 2023, then crashed by 41.73% to $111.8 million in 2024, then tumbled by 42.12% to $64.7 million in 2025.
  • Its Invested Capital stands at $64.7 million for Q3 2025, versus $79.3 million for Q2 2025 and $93.5 million for Q1 2025.